0001554795-19-000236.txt : 20190809 0001554795-19-000236.hdr.sgml : 20190809 20190809152241 ACCESSION NUMBER: 0001554795-19-000236 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 26 CONFORMED PERIOD OF REPORT: 20190630 FILED AS OF DATE: 20190809 DATE AS OF CHANGE: 20190809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CANCER CAPITAL CORP CENTRAL INDEX KEY: 0001130889 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 911803648 STATE OF INCORPORATION: WY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-32363 FILM NUMBER: 191012776 BUSINESS ADDRESS: STREET 1: 2157 S. LINCOLN CITY: SALT LAKE CITY STATE: UT ZIP: 84106 BUSINESS PHONE: 801-323-2395 MAIL ADDRESS: STREET 1: 2157 S. LINCOLN CITY: SALT LAKE CITY STATE: UT ZIP: 84106 10-Q 1 cncl0806form10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☑

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2019

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___ to ___

Commission file number: 000-32363

CANCER CAPITAL CORP.

(Exact name of registrant as specified in its charter)

Wyoming

(State or other jurisdiction of incorporation or organization)

91-1803648

(I.R.S. Employer Identification No.)

2157 S. Lincoln Street, Salt Lake City, Utah

(Address of principal executive offices)

84106

(Zip code)

(801) 323-2395

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐

Non-accelerated filer ☑

Accelerated filer ☐

Smaller reporting company ☑

Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☑ No ☐

The number of shares outstanding of the registrant’s common stock as of August 7, 2019 was 6,150,000.

TABLE OF CONTENTS

	PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)	3
	Condensed Balance Sheets (Unaudited)	4
	Condensed Statements of Operations (Unaudited)	5
	Condensed Statement of Stockholders’ Deficit (Unaudited)	6
	Condensed Statements of Cash Flows (Unaudited)	7
	Condensed Notes to the Unaudited Financial Statements	8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	9
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	11
Item 4.	Controls and Procedures	11

	PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	12
Item 1a.	Risk Factors Information	12
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	12
Item 3.	Defaults Upon Senior Securities	12
Item 4.	Mine Safety Disclosures	12
Item 5.	Other Information	12
Item 6.	Exhibits	12
Signatures		13

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

CANCER CAPITAL CORP.

Condensed Financial Statements

June 30, 2019

(Unaudited)

Cancer Capital Corp.

Condensed Balance Sheets

(Unaudited)

	JUNE 30, 2019			DEC 31, 2018

ASSETS
CURRENT ASSETS
Cash	$	243		$	168
Total current assets		243			168
Total assets	$	243		$	168

LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES
Accounts payable – related party	$	9,600		$	6,600
Accounts payable		1,200			1,100
Notes payable – related party		117,925			112,825
Notes payable		82,575			82,575
Accrued interest – related party		39,504			34,948
Accrued interest		37,513			34,211
Total current liabilities		288,317			272,259
Total liabilities		288,317			272,259

STOCKHOLDERS' DEFICIT
Common stock, $.001 par value; 20,000,000 shares authorized; 6,150,000 shares issued and outstanding		6,150			6,150
Additional paid-in capital		47,050			47,050
Accumulated deficit		(341,274	)		(325,291	)
Total stockholders' deficit		(288,074	)		(272,091	)
Total liabilities and stockholders' deficit	$	243		$	168

The accompanying notes are an integral part of these unaudited condensed financial statements.

Cancer Capital Corp.

Condensed Statements of Operations

(Unaudited)

	FOR THE THREE MONTHS ENDED JUNE 30, 2019			FOR THE THREE MONTHS ENDED JUNE 30, 2018			FOR THE SIX MONTHS ENDED JUNE 30, 2019			FOR THE SIX MONTHS ENDED JUNE 30, 2018

Revenues	$	—		$	—		$	—		$	—

Expenses
General and administrative		2,710			2,605			8,125			8,317
Total expenses		2,710			2,605			8,125			8,317

Loss from operations before other expense		(2,710	)		(2,605	)		(8,125	)		(8,317	)

Other income (expense) non-operating
Interest expense – related party		(2,313	)		(2,085	)		(4,556	)		(4,095	)
Interest expense		(1,651	)		(1,651	)		(3,302	)		(3,302	)
Total other expense		(3,964	)		(3,736	)		(7,858	)		(7,397	)

Loss from operations before taxes		(6,674	)		(6,341	)		(15,983	)		(15,714	)

Taxes		—			—			—			—

Net loss	$	(6,674	)	$	(6,341	)	$	(15,983	)	$	(15,714	)

Net loss per share – Basic and diluted	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)

Weighted average shares outstanding		6,150,000			6,150,000			6,150,000			6,150,000

The accompanying notes are an integral part of these unaudited condensed financial statements.

Cancer Capital Corp.

Statement of Stockholders Equity (Deficit)

For the six months ended June 30, 2018 and 2019

(Unaudited)

	Common Stock				Additional paid-in capital		Accumulated deficit			Total
	Shares		Amount

Balance – December 31, 2017		6,150,000	$	6,150	$	47,050	$	(296,821	)	$	(243,621	)
Net income (loss) for the quarter ended - March 31, 2018		—		—		—		(9,373	)		(9,373	)
Balance – March 31, 2018		6,150,000	$	6,150	$	47,050	$	(306,194	)	$	(252,994	)
Net income (loss) for the quarter ended – June 30, 2018		—		—		—		(6,341	)		(6,341	)
Balance – June 30, 2018		6,150,000	$	6,150	$	47,050	$	(312,535	)	$	(259,335	)

Balance – December 31, 2018		6,150,000	$	6,150		47,050	$	(325,291	)	$	(272,091	)
Net income (loss) for the quarter ended - March 31, 2019		—		—		—		(9,309	)		(9,309	)
Balance – March 31, 2019		6,150,000	$	6,150		47,050	$	(334,600	)	$	(281,400	)
Net income (loss) for the quarter ended - June 30, 2019		—		—		—		(6,674	)		(6,674	)
Balance – June 30, 2019		6,150,000	$	6,150		47,050	$	(341,274	)	$	(288,074	)

The accompanying notes are an integral part of these unaudited condensed financial statements.

Cancer Capital Corp.

Condensed Statements of Cash Flows

(Unaudited)

	FOR THE SIX MONTHS ENDED JUNE 30, 2019			FOR THE SIX MONTHS ENDED JUNE 30, 2018

Cash Flows from Operating Activities
Net Loss	$	(15,983	)	$	(15,714	)
Adjustment to reconcile net loss to cash provided (used) by operating activities:
Expenses paid by related party		3,000			3,600
Changes in operating assets and liabilities:
Accounts payable		100			—
Increase in accrued interest – related party		4,556			4,095
Increase in accrued interest		3,302			3,302
Net cash provided (used) by operating activities		(5,025	)		(4,717	)

Cash Flows from Investing Activities
Net cash provided by investing activities		—			—

Cash Flows from Financing Activities
Proceeds from notes payable – related party		5,100			4,500
Net cash provided by financing activities		5,100			4,500

Increase (decrease) in cash		75			(217	)

Cash and cash equivalents at beginning of period		168			315

Cash and cash equivalents at end of period	$	243		$	98

Supplemental Cash Flow Information:
Cash paid for interest	$	—		$	—
Cash paid for income taxes	$	—		$	—

The accompanying notes are an integral part of these unaudited condensed financial statements.

Cancer Capital Corp.

Notes to the Condensed Financial Statements

(Unaudited)

June 30, 2019

NOTE 1 – BASIS OF FINANCIAL STATEMENT PRESENTATION

The accompanying unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted in accordance with such rules and regulations. The information furnished in the interim condensed financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements. Although management believes the disclosures and information presented are adequate to make the information not misleading, it is suggested that these interim condensed financial statements be read in conjunction with the Company’s audited financial statements and notes thereto included in its December 31, 2018 Annual Report on Form 10-K. Operating results for the six months ended June 30, 2019 are not necessarily indicative of the results to be expected for year ending December 31, 2019.

NOTE 2 – GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has limited assets, has incurred losses since inception, has negative cash flows from operations, and has no revenue-generating activities. Its activities have been limited for the past several years and it is dependent upon financing to continue operations. These factors raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. It is management’s plan to acquire or merge with other operating companies.

NOTE 3 – RELATED PARTY TRANSACTIONS

During the six months ended June 30, 2019, a shareholder, invoiced the Company for consulting, administrative and professional services and out-of-pocket costs provided or paid on behalf of the Company totaling $3,000, resulting in the Company owing the shareholder $9,600 and $6,600 at June 30, 2019 and December 31, 2018, respectively.

During the six months ended June 30, 2019, a shareholder loaned the Company $5,100. The notes bear interest at 8% and are due on demand. Notes payable – related party at June 30, 2019 and December 31, 2018 were $117,925 and $112,825, respectively. Accrued interest at June 30, 2019 and December 31, 2018 was $39,504 and $34,948, respectively.

NOTE 4 – SUBSEQUENT EVENTS

The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and has determined that there are no such events that would have a material impact on the financial statements.

FORWARD LOOKING STATEMENTS

The Securities and Exchange Commission (“SEC”) encourages companies to disclose forward-looking information so that investors can better understand future prospects and make informed investment decisions. This report contains these types of statements. Words such as “may,” “intend,” “expect,” “believe,” “anticipate,” “estimate,” “project,” or “continue” or comparable terminology used in connection with any discussion of future operating results or financial performance identify forward-looking statements. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this report. All forward-looking statements reflect our present expectation of future events and are subject to a number of important factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

In this report references to “Cancer Capital,” “the Company,” “we,” “us,” and “our” refer to Cancer Capital Corp.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Executive Overview

We have not recorded revenues since inception and we are dependent upon financing to continue basic operations. Management intends to rely upon advances or loans from management, significant stockholders or third parties to meet our cash requirements, but we have not entered into written agreements guaranteeing funds and, therefore, no one is obligated to provide funds to us in the future. These factors raise substantial doubt as to our ability to continue as a going concern. Our plan is to combine with an operating company to generate revenue.

As of the date of this report, our management has not had any discussions with any representative of any other entity regarding a business combination with us. Any target business that is selected may be a financially unstable company or an entity in its early stages of development or growth, including entities without established records of sales or earnings. In that event, we will be subject to numerous risks inherent in the business and operations of financially unstable and early stage or potential emerging growth companies. In addition, we may effect a business combination with an entity in an industry characterized by a high level of risk, and, although our management will endeavor to evaluate the risks inherent in a particular target business, there can be no assurance that we will properly ascertain or assess all significant risks. In addition, any business combination or transaction will likely result in a significant issuance of shares and substantial dilution to present stockholders of the Company.

We anticipate that the selection of a business opportunity will be complex and extremely risky. Because of general economic conditions, rapid technological advances being made in some industries and shortages of available capital, our management believes that there are numerous firms seeking the perceived benefits of becoming a publicly traded corporation. Such perceived benefits of becoming a publicly traded corporation include, among other things, facilitating or improving the terms on which additional equity financing may be obtained, providing liquidity for the principals of and investors in a business, creating a means for providing incentive stock options or similar benefits to key employees, and offering greater flexibility in structuring acquisitions, joint ventures and the like through the issuance of securities. Potentially available business combinations may occur in many different industries and at various stages of development, all of which will make the task of comparative investigation and analysis of such business opportunities extremely difficult and complex.

If we obtain a business opportunity, then it may be necessary to raise additional capital. We anticipate that we will sell our common stock to raise this additional capital. We expect that we would issue such stock pursuant to exemptions to the registration requirements provided by federal and state securities laws. The purchasers and manner of issuance will be determined according to our financial needs and the available exemptions to the registration requirements of the Securities Act of 1933. We do not currently intend to make a public offering of our stock. We also note that if we issue more shares of our common stock, then our stockholders may experience dilution in the value per share of their common stock.

Liquidity and Capital Resources

We have not recorded revenues from operations since inception and we have not established an ongoing source of revenue sufficient to cover our operating costs. We have relied primarily upon related and third parties to provide and pay for professional and operational expenses. At June 30, 2019 we had $243 cash compared to $168 at December 31, 2018. At June 30, 2019 total liabilities increased to $288,317 compared to $272,259 at December 31, 2018. This increase in total liabilities represents increases of accounts payable to vendors, accounts payable – related party for consulting services and professional services provided by or paid for by a stockholder, loans from a shareholder and accrued interest.

We intend to obtain capital from management, significant stockholders and/or third parties to cover minimal operations; however, there is no assurance that additional funding will be available. Our ability to continue as a going concern during the long term is dependent upon our ability to find a suitable business opportunity and acquire or enter into a merger with such company. The type of business opportunity with which we acquire or merge will affect our profitability for the long term.

During the next 12 months we anticipate incurring additional costs related to the filing of Exchange Act reports. We believe we will be able to meet these costs through funds provided by management, significant stockholders and/or third parties. We may also rely on the issuance of our common stock in lieu of cash to convert debt or pay for expenses.

Results of Operations

We did not record revenues in either 2019 or 2018. General and administrative expense decreased to $8,125 for the six months ended June 30, 2019 (“2019 six month period”) compared to $8,317 for the six months ended June 30, 2018 (“2018 six month period”). The decrease for the 2019 six month period was primarily due to reduced accounts payable. General and administrative expense increased to $2,710 for the three months ended June 30, 2019 (“2019 second quarter”) compared to $2,605 for the three months ended June 30, 2018 (“2018 second quarter”).

Total other expense increased to $7,858 for the 2019 six month period compared to $7,397 for the 2018 six month period. Total other expense increased to $3,964 for the 2019 second quarter compared to $3,736 for the 2018 second quarter. Total other expense represents interest expense related to notes payable.

Our net loss increased to $15,983 for the 2019 six month period compared to $15,714 for the 2018 six month period. Our net loss increased to $6,674 for the 2019 second quarter compared to $6,341 for the 2018 second quarter. Management expects net losses to continue until we acquire or merge with a business opportunity.

Commitments and Obligations

At June 30, 2019 we reported notes payable totaling $82,575 and notes payable-related party of $117,925. All of the notes payable are non-collateralized, carry interest at 8% and are due on demand. Total accrued interest on all notes payable was $77,017 at June 30, 2019.

At June 30, 2019 accounts payable-related party increased to $9,600 due to $3,000 paid for consulting services and professional services provided by or paid for by a stockholder during the 2019 six month period. Accounts payable, representing amounts owed to vendors, increased to $1,200 for the 2019 six month period.

As of June 30, 2019, two lenders represent in excess of 95% of our accounts and notes payable.

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.

Emerging Growth Company

We qualify as an emerging growth company as that term is used in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). A company qualifies as an emerging growth company if it has total annual gross revenues of less than $1.07 billion during its most recently completed fiscal year and, as of December 8, 2011, had not sold common equity securities under a registration statement. Under the JOBS Act we are permitted to, and intend to, rely on exemptions from certain disclosure requirements

In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable to smaller reporting companies.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported within the periods specified in the rules and forms of the SEC. This information is accumulated to allow our management to make timely decisions regarding required disclosure. Our President, who serves as our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report and he determined that our disclosure controls and procedures were not effective due to a control deficiency. During the period we did not have additional personnel to allow segregation of duties to ensure the completeness or accuracy of our information. Due to the size and operations of the Company we are unable to remediate this deficiency until we acquire or merge with another company.

Changes to Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Management conducted an evaluation of our internal control over financial reporting and determined that there were no changes made in our internal control over financial reporting during the quarter ended June 30, 2019 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We know of no material, existing or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our company.

ITEM 1A. RISK FACTORS

As a smaller reporting company we are not required to provide the information required by this Item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

Part I Exhibits

No.	Description
31.1	Principal Executive Officer Certification
31.2	Principal Financial Officer Certification
32.1	Section 1350 Certification

Part II Exhibits

No.	Description
3(i)	Wyoming Articles of Domestication for Cancer Capital, dated April 28, 2016 (Incorporated by reference to exhibit 3(i) to Form 10-Q, filed May 13, 2016)
3(ii)	Bylaws of Cancer Capital, dated May 2, 2016 (Incorporated by reference to exhibit 3(ii) to Form 10-Q, filed May 13, 2016)
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Calculation Linkbase Document
101.CAL	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Label Linkbase Document
101.PRE	XBRL Taxonomy Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 9, 2019

CANCER CAPITAL CORP.

By: /s/ John W. Peters

John W. Peters

President and Director

Principal Financial Officer

EX-31.1 2 cncl0806form10qexh31_1.htm EXHIBIT 31.1

Exhibit 31.1

PRINCIPAL EXECUTIVE OFFICER CERTIFICATION

I, John W. Peters, certify that:

I have reviewed this quarterly report on Form 10-Q of Cancer Capital Corp.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statement made, in light of the circumstances under which statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 9, 2019

/s/ John W. Peters

John W. Peters

Principal Executive Officer

EX-31.2 3 cncl0806form10qexh31_2.htm EXHIBIT 31.2

Exhibit 31.2

PRINCIPAL FINANCIAL OFFICER CERTIFICATION

I, John W. Peters, certify that:

I have reviewed this quarterly report on Form 10-Q of Cancer Capital Corp.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 9, 2019

/s/ John W. Peters

John W. Peters

Principal Financial Officer

EX-32.1 4 cncl0806form10qexh32_1.htm EXHIBIT 32.1

Exhibit 32.1

CANCER CAPITAL CORP.

CERTIFICATION OF PERIODIC REPORT

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

18 U.S.C. Section 1350

The undersigned executive officer of Cancer Capital Corp. certifies pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that:

the quarterly report on Form 10-Q of Cancer Capital Corp. for the quarter ended June 30, 2019 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Cancer Capital Corp.

Date: August 9, 2019

/s/ John W. Peters

John W. Peters

Principal Executive Officer

Principal Financial Officer

EX-101.INS 5 cncl-20190630.xml XBRL INSTANCE FILE 0001130889 2019-01-01 2019-06-30 0001130889 2019-08-07 0001130889 2019-06-30 0001130889 2018-12-31 0001130889 2018-01-01 2018-06-30 0001130889 2017-12-31 0001130889 us-gaap:CommonStockMember 2017-12-31 0001130889 us-gaap:CommonStockMember 2018-12-31 0001130889 us-gaap:CommonStockMember 2019-06-30 0001130889 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001130889 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001130889 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001130889 us-gaap:RetainedEarningsMember 2017-12-31 0001130889 us-gaap:RetainedEarningsMember 2018-12-31 0001130889 us-gaap:RetainedEarningsMember 2019-06-30 0001130889 2018-06-30 0001130889 us-gaap:CommonStockMember 2018-06-30 0001130889 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001130889 us-gaap:RetainedEarningsMember 2018-06-30 0001130889 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001130889 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001130889 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001130889 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001130889 us-gaap:CommonStockMember 2018-03-31 0001130889 us-gaap:CommonStockMember 2019-03-31 0001130889 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001130889 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001130889 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001130889 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001130889 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001130889 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001130889 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001130889 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001130889 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001130889 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001130889 us-gaap:RetainedEarningsMember 2018-03-31 0001130889 us-gaap:RetainedEarningsMember 2019-03-31 0001130889 2018-01-01 2018-03-31 0001130889 2018-04-01 2018-06-30 0001130889 2019-01-01 2019-03-31 0001130889 2019-04-01 2019-06-30 0001130889 2018-03-31 0001130889 2019-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

0.001

20000000

6150000

NOTE 4 – SUBSEQUENT EVENTS   The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and has determined that there are no such events that would have a material impact on the financial statements.

NOTE 2 – GOING CONCERN   The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has limited assets, has incurred losses since inception, has negative cash flows from operations, and has no revenue-generating activities. Its activities have been limited for the past several years and it is dependent upon financing to continue operations. These factors raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. It is management’s plan to acquire or merge with other operating companies.

NOTE 3 – RELATED PARTY TRANSACTIONS   During the six months ended June 30, 2019, a shareholder, invoiced the Company for consulting, administrative and professional services and out-of-pocket costs provided or paid on behalf of the Company totaling $3,000, resulting in the Company owing the shareholder $9,600 and $6,600 at June 30, 2019 and December 31, 2018, respectively.   During the six months ended June 30, 2019, a shareholder loaned the Company $5,100. The notes bear interest at 8% and are due on demand. Notes payable – related party at June 30, 2019 and December 31, 2018 were $117,925 and $112,825, respectively. Accrued interest at June 30, 2019 and December 31, 2018 was $39,504 and $34,948, respectively.

9600

6600

39504

34948

NOTE 1 – BASIS OF FINANCIAL STATEMENT PRESENTATION   The accompanying unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted in accordance with such rules and regulations. The information furnished in the interim condensed financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements. Although management believes the disclosures and information presented are adequate to make the information not misleading, it is suggested that these interim condensed financial statements be read in conjunction with the Company’s audited financial statements and notes thereto included in its December 31, 2018 Annual Report on Form 10-K. Operating results for the six months ended June 30, 2019 are not necessarily indicative of the results to be expected for year ending December 31, 2019.

3000

0.08

5100

CANCER CAPITAL CORP 0001130889 10-Q 2019-06-30 Yes Yes true true WY --12-31 false 000-32363 false Non-accelerated Filer 6150000 Q2 2019

243

168

243

168

243

168

315

288317

272259

288317

272259

37513

34211

39504

34948

82575

117925

112825

1200

1100

9600

6600

243

168

-288074

-272091

-243621

6150

47050

-296821

-325291

-341274

-259335

6150

47050

-312535

6150

47050

-306194

-334600

-252994

-281400

-341274

-325291

47050

6150

8125

8317

2605

2710

8125

8317

2605

2710

-8125

-8317

-2605

-2710

-7858

-7397

-3736

-3964

3302

1651

4556

4095

2085

2313

-15983

-15714

-6341

-6674

-15983

-15714

-9373

-6341

-9309

-6674

-9373

-6341

-9309

-6674

-0.00

6150000

3000

3600

-5025

-4717

3302

4556

4095

100

5100

4500

5100

4500

-217

EX-101.SCH 6 cncl-20190630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statement of Stockholders’ Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Basis of Financial Statement Presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 cncl-20190630_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 cncl-20190630_def.xml XBRL DEFINITION FILE EX-101.LAB 9 cncl-20190630_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock Additional Paid-In Capital Accumulated Deficit Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Entity Incorporation, State or Country Code Amendment Flag Amendment Description Current Fiscal Year End Date Entity File Number Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Interactive Data Current Is Entity Emerging Growth Company? Elected Not To Use the Extended Transition Period Entity Filer Category Entity Small Business Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Entity Shell Company Statement of Financial Position [Abstract] ASSETS Current Assets Cash Total current assets Total assets LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities Accounts payable - related party Accounts payable Notes payable - related party Notes payable Accrued interest - related party Accrued interest Total current liabilities Total liabilities STOCKHOLDERS' DEFICIT Common stock, $.001 par value; 20,000,000 shares authorized; 6,150,000 shares issued and outstanding Additional paid in capital Accumulated deficit Stotal stockholders' deficit Total liabilities and stockholders' deficit Common stock, par value Common stock, authorized Common stock, issued Common stock, outstanding Income Statement [Abstract] REVENUES EXPENSES General and administrative Total expenses Loss from operations before other expense Other income (expense) non-operating Interest expense - related party Interest expense Total other expense Loss from operations before taxes Taxes Net loss Net loss per share - Basic and diluted Weighted average shares outstanding Statement [Table] Statement [Line Items] Beginning balance, shares Beginning balance, amount Net loss Ending balance, shares Ending balance, amount Statement of Cash Flows [Abstract] Cash Flows from Operating Activities Net Loss Adjustments to reconcile net loss to cash provided (used) by operating activities: Expenses paid by related party Changes in assets and liabilities: Accounts payable Increase in accrued interest - related party Increase in accrued interest Net cash provided (used) by operating activities Cash Flows from Investing Activities Net cash provided by investing activities Cash Flows from Financing Activities Proceeds from notes payable - related party Net cash provided by financing activities Increase (decrease) in cash Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental Cash Flow Information: Cash paid for interest Cash paid for income taxes Organization, Consolidation and Presentation of Financial Statements [Abstract] Basis of Financial Statement Presentation GOING CONCERN Related Party Transactions [Abstract] Related Party Transactions Subsequent Events [Abstract] Subsequent Events Consulting, administrative and professional costs provided for or paid on behalf of Company by shareholder Amounts due to shareholder Amounts loaned to Company by shareholder Accrued interest on notes payable - related party Interest rate on notes payable - related party Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense, Related Party Interest Expense Other Operating Income (Expense), Net Income (Loss) from Continuing Operations before Income Taxes, Domestic Increase (Decrease) in Income Taxes Shares, Outstanding Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Financing Activities Cash, Period Increase (Decrease) EX-101.PRE 10 cncl-20190630_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2019	Aug. 07, 2019
Document And Entity Information
Entity Registrant Name	CANCER CAPITAL CORP
Entity Central Index Key	0001130889
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Entity Incorporation, State or Country Code	WY
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity File Number	000-32363
Is Entity's Reporting Status Current?	Yes
Entity Interactive Data Current	Yes
Is Entity Emerging Growth Company?	true
Elected Not To Use the Extended Transition Period	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Common Stock, Shares Outstanding		6,150,000
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Current Assets
Cash	$ 243	$ 168
Total current assets	243	168
Total assets	243	168
Current Liabilities
Accounts payable - related party	9,600	6,600
Accounts payable	1,200	1,100
Notes payable - related party	117,925	112,825
Notes payable	82,575	82,575
Accrued interest - related party	39,504	34,948
Accrued interest	37,513	34,211
Total current liabilities	288,317	272,259
Total liabilities	288,317	272,259
STOCKHOLDERS' DEFICIT
Common stock, $.001 par value; 20,000,000 shares authorized; 6,150,000 shares issued and outstanding	6,150	6,150
Additional paid in capital	47,050	47,050
Accumulated deficit	(341,274)	(325,291)
Stotal stockholders' deficit	(288,074)	(272,091)
Total liabilities and stockholders' deficit	$ 243	$ 168

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	20,000,000	20,000,000
Common stock, issued	6,150,000	6,150,000
Common stock, outstanding	6,150,000	6,150,000

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
REVENUES
EXPENSES
General and administrative	2,710	2,605	8,125	8,317
Total expenses	2,710	2,605	8,125	8,317
Loss from operations before other expense	(2,710)	(2,605)	(8,125)	(8,317)
Other income (expense) non-operating
Interest expense - related party	(2,313)	(2,085)	(4,556)	(4,095)
Interest expense	(1,651)	(1,651)	(3,302)	(3,302)
Total other expense	(3,964)	(3,736)	(7,858)	(7,397)
Loss from operations before taxes	(6,674)	(6,341)	(15,983)	(15,714)
Taxes
Net loss	$ (6,674)	$ (6,341)	$ (15,983)	$ (15,714)
Net loss per share - Basic and diluted	$ (0.00)	$ (0.00)	$ (0.00)	$ (0.00)
Weighted average shares outstanding	6,150,000	6,150,000	6,150,000	6,150,000

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Statement of Stockholders’ Deficit (Unaudited) - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning balance, shares at Dec. 31, 2017	6,150,000
Beginning balance, amount at Dec. 31, 2017	$ 6,150	$ 47,050	$ (296,821)	$ (243,621)
Net loss			(9,373)	(9,373)
Ending balance, shares at Mar. 31, 2018	6,150,000
Ending balance, amount at Mar. 31, 2018	$ 6,150	47,050	(306,194)	(252,994)
Beginning balance, shares at Dec. 31, 2017	6,150,000
Beginning balance, amount at Dec. 31, 2017	$ 6,150	47,050	(296,821)	(243,621)
Net loss				(15,714)
Ending balance, shares at Jun. 30, 2018	6,150,000
Ending balance, amount at Jun. 30, 2018	$ 6,150	47,050	(312,535)	(259,335)
Beginning balance, shares at Mar. 31, 2018	6,150,000
Beginning balance, amount at Mar. 31, 2018	$ 6,150	47,050	(306,194)	(252,994)
Net loss			(6,341)	(6,341)
Ending balance, shares at Jun. 30, 2018	6,150,000
Ending balance, amount at Jun. 30, 2018	$ 6,150	47,050	(312,535)	(259,335)
Beginning balance, shares at Dec. 31, 2018	6,150,000
Beginning balance, amount at Dec. 31, 2018	$ 6,150	47,050	(325,291)	(272,091)
Net loss			(9,309)	(9,309)
Ending balance, shares at Mar. 31, 2019	6,150,000
Ending balance, amount at Mar. 31, 2019	$ 6,150	47,050	(334,600)	(281,400)
Beginning balance, shares at Dec. 31, 2018	6,150,000
Beginning balance, amount at Dec. 31, 2018	$ 6,150	47,050	(325,291)	(272,091)
Net loss				(15,983)
Ending balance, shares at Jun. 30, 2019	6,150,000
Ending balance, amount at Jun. 30, 2019	$ 6,150	47,050	(341,274)	(288,074)
Beginning balance, shares at Mar. 31, 2019	6,150,000
Beginning balance, amount at Mar. 31, 2019	$ 6,150	47,050	(334,600)	(281,400)
Net loss			(6,674)	(6,674)
Ending balance, shares at Jun. 30, 2019	6,150,000
Ending balance, amount at Jun. 30, 2019	$ 6,150	$ 47,050	$ (341,274)	$ (288,074)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash Flows from Operating Activities
Net Loss	$ (15,983)	$ (15,714)
Adjustments to reconcile net loss to cash provided (used) by operating activities:
Expenses paid by related party	3,000	3,600
Changes in assets and liabilities:
Accounts payable	100
Increase in accrued interest - related party	4,556	4,095
Increase in accrued interest	3,302	3,302
Net cash provided (used) by operating activities	(5,025)	(4,717)
Cash Flows from Investing Activities
Net cash provided by investing activities
Cash Flows from Financing Activities
Proceeds from notes payable - related party	5,100	4,500
Net cash provided by financing activities	5,100	4,500
Increase (decrease) in cash	75	(217)
Cash and cash equivalents at beginning of period	168	315
Cash and cash equivalents at end of period	243	98
Supplemental Cash Flow Information:
Cash paid for interest
Cash paid for income taxes

XML 17 R7.htm IDEA: XBRL DOCUMENT

Basis of Financial Statement Presentation

6 Months Ended

Jun. 30, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Financial Statement Presentation

NOTE 1 – BASIS OF FINANCIAL STATEMENT PRESENTATION

XML 18 R8.htm IDEA: XBRL DOCUMENT

Going Concern

6 Months Ended

Jun. 30, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GOING CONCERN

NOTE 2 – GOING CONCERN

XML 19 R9.htm IDEA: XBRL DOCUMENT

Related Party Transactions

6 Months Ended

Jun. 30, 2019

Related Party Transactions

NOTE 3 – RELATED PARTY TRANSACTIONS

XML 20 R10.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Jun. 30, 2019

Subsequent Events [Abstract]

Subsequent Events

NOTE 4 – SUBSEQUENT EVENTS

XML 21 R11.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Related Party Transactions [Abstract]
Consulting, administrative and professional costs provided for or paid on behalf of Company by shareholder	$ 3,000
Amounts due to shareholder	9,600	$ 6,600
Amounts loaned to Company by shareholder	5,100
Notes payable - related party	117,925	112,825
Accrued interest on notes payable - related party	$ 39,504	$ 34,948
Interest rate on notes payable - related party	8.00%

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end